United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 7,700 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

United Therapeutics stock opened at $369.67 on Friday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The company’s 50-day moving average is $369.14 and its 200 day moving average is $338.62. The firm has a market capitalization of $16.51 billion, a P/E ratio of 16.23, a price-to-earnings-growth ratio of 1.09 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the company earned $5.38 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. ClariVest Asset Management LLC boosted its position in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in shares of United Therapeutics in the second quarter worth $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $33,000. USA Financial Formulas acquired a new stake in United Therapeutics during the 3rd quarter worth about $33,000. Finally, Brooklyn Investment Group purchased a new stake in United Therapeutics during the 3rd quarter valued at about $33,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on UTHR. Jefferies Financial Group lifted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Argus upped their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.